<DOC>
	<DOCNO>NCT01977794</DOCNO>
	<brief_summary>This randomize , comparative Phase 3 trial investigate efficacy fix dose combination ( FDC ) bisoprolol amlodipine hypertensive subject ( superiority FDC monotherapies ) .</brief_summary>
	<brief_title>Fixed Dose Combination Bisoprolol Amlodipine Treatment Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<criteria>Essential hypertension control 5 mg bisoprolol 5 mg amlodipine least 4 week ( definition control : SBP great equal ( &gt; = ) 140 millimeter mercury ( mmHg ) without DBP &gt; = 90 mmHg ) Male female subject &gt; =18 year age , without limitation race Medically accept effective contraception procreative potential exists ( applicable male female subject least 90 day last dose trial treatment ) Subjects sign informed consent form trial relate assessment General contraindication betablockers and/or calcium channel blocker Previous concurrent acute heart failure episodes heart failure decompensation require intravenous inotropic therapy Concurrent cardiogenic shock Previous concurrent second third degree atrioventricular ( AV ) block ( without pacemaker ) Previous concurrent sick sinus syndrome Previous concurrent sinoatrial block Concurrent symptomatic bradycardia Concurrent symptomatic hypotension Previous concurrent severe bronchial asthma chronic obstructive pulmonary disease Previous concurrent severe peripheral arterial occlusive disease Raynaud 's syndrome Untreated pheochromocytoma Concurrent metabolic acidosis Known hypersensitivity bisoprolol , amlodipine , dihydropyridine derivates excipients Seated pulse rate le 60 beat per minute ( bpm ) screen Any antihypertensive drug ( bisoprolol amlodipine ) use within 4 week prior screen visit Use enzymemodifying drug act cytochrome P450 ( CYP ) 3A4 enzyme via inhibition ( ketoconazole , itraconazole , ritonavir ) induction ( rifampicin hypericum perforatum ) within 28 day Day 1 trial Other significant disease Investigator 's opinion would exclude subject trial , uncontrolled diabetes mellitus , severe liver and/or kidney dysfunction , decompensated cardiac failure Any condition therapy Investigator 's opinion would pose risk subject interfere trial objective Concurrent alcohol and/or drug abuse Known hypersensitivity trial treatment Pregnancy lactation period . All female subject reproductive potential must negative pregnancy serum test within 7 day prior enrollment Known lack subject compliance Legal incapacity limit legal capacity Participation another clinical trial within previous 30 day Persons directly involve execution protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Bisoprolol</keyword>
	<keyword>Amlodipine</keyword>
	<keyword>Fixed dose combination ( FDC )</keyword>
	<keyword>Systolic Blood Pressure ( SBP )</keyword>
	<keyword>Diastolic Blood Pressure ( DBP )</keyword>
</DOC>